Skip to main content
Premium Trial:

Request an Annual Quote

VizX Aims at Becoming Cash-Flow Positive by End of Year

NEW YORK, July 24 - Informatics company VizX labs intends to be cash-flow positive at the end of the year, according to an e-mail message from CEO and co-founder Thomas Ranken.


"We will develop the capacity to expand our company from new funding sources: earnings, investment, and debt," said Ranken.


VizX makes the gene expression-analysis software, a new version of which was launched earlier this month. Besides becoming cash-flow positive, Ranken said the company's "top priority" is to "build sales" for the software, which he said is responsible for the lion's share of the company's revenue.


Reached by telephone in VizX's Seattle, Wash., headquarters, Ranken said the firm intends to increase its sales staff and enter into new distribution deals.


VizX has been funded by angel investors up until now, Ranken said. He added the company is wrapping up a convertible-note round, and is talking to venture capitalists. "But ... the market is very tough."

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.